Chemours (CC) Q4 2025 earnings review
TSS Shines, But Industrial Segments Collapse
Chemours delivered a sharply bifurcated Q4. The Thermal & Specialized Solutions (TSS) segment posted a record quarter with 14% sales growth driven by the Opteon regulatory transition. However, the industrial segments (Titanium Technologies and Advanced Performance Materials) crumbled under cyclical pressure and deliberate production cuts to manage cash. Consolidated Adjusted EBITDA fell 24% YoY to $128 million, missing the prior year's $168 million. Margins in TT and APM compressed to a razor-thin 4%, dragging the company into a $47 million net loss. While FY26 guidance ($800-900M EBITDA) implies a recovery from FY25 ($742M), the Q1 outlook suggests the turning point is not yet immediate.
🐂 Bull Case
The transition to low-GWP refrigerants (Opteon) is a powerful, non-cyclical tailwind. TSS sales grew 13% in FY25 to a record $2.1B, with Opteon refrigerants specifically growing double-digits (+37% in Q4). This segment now anchors the company's profitability.
Despite the earnings miss, Free Cash Flow Conversion hit 72% in Q4 ($92M), significantly higher than the 17% in the prior year. Management prioritized cash over earnings by cutting production to lower inventory, a painful but necessary move to defend the balance sheet.
🐻 Bear Case
Titanium Technologies and APM both reported Adjusted EBITDA margins of just 4% in Q4—levels that indicate severe operating leverage issues. TT EBITDA fell 67% YoY, and APM fell 74%. Recovery relies on a macro turnaround that hasn't materialized yet.
Net leverage stands at 4.7x Adjusted EBITDA, far above the company's long-term target of <3.0x. With Q1 26 EBITDA guided to $120-150M (down from $166M in 25Q1), deleveraging will be slow.
⚖️ Verdict: 🔴
Bearish. The TSS story is excellent, but it cannot single-handedly carry the dead weight of the TT and APM segments, which are currently barely profitable. Until industrial demand bottoms and production rates normalize, earnings quality remains poor.
Key Themes
Titanium Technologies Profitability Collapse
TT Adjusted EBITDA margin collapsed to 4% in Q4 from 11% a year ago and 12% in FY24. The segment was hit by a 'double whammy': weak pricing (-6% YoY) due to global competition and significant unabsorbed fixed costs from production cuts aimed at generating cash. Management announced a Dec 1 price hike, but its impact is yet to be seen in the numbers.
Opteon Regulatory Tailwind
TSS continues to defy the industrial slowdown, with Opteon Refrigerants sales up 37% YoY in Q4 and 56% for the full year. The U.S. AIM Act is driving a mandatory transition to these higher-value blends in stationary air conditioning. This structural shift is durable and high-margin (TSS EBITDA margin ~29-35%).
APM Operational & Market Headwinds
Advanced Performance Materials posted a 74% decline in EBITDA YoY. Beyond weak market demand, the segment incurred a non-cash inventory charge and costs related to idling production. The 4% margin in Q4 is a sharp deterioration from the 15% seen a year ago, raising questions about the segment's fixed cost structure in a downturn.
Asset Monetization
To shore up liquidity, Chemours announced the sale of its Kuan Yin TiO2 site for ~$300M net proceeds. This aligns with the strategy to prioritize cash flow and manage leverage (4.7x) amidst earnings pressure.
Other KPIs
Decelerating. Down 24% YoY ($168M) and 34% sequentially ($189M). The result reflects the severe impact of under-absorption charges in TT and APM. FY25 EBITDA of $742M finished below the prior year's $768M.
Accelerating. Up significantly from $29M in 24Q4. Despite lower earnings, aggressive working capital management (inventory reduction efforts) drove a 72% conversion rate, well above the 17% in the prior year period.
Stable/High. Leverage remains elevated (vs ~2.8x at end of 2023). Reducing this relies heavily on the projected FY26 EBITDA recovery to $800-900M and asset sale proceeds.
Guidance
Stabilizing. Implies sales of ~$1.37B-$1.39B. While sequentially positive due to seasonal TSS demand and a TT rebound, it implies relatively flat performance vs 25Q1 ($1.37B), suggesting no immediate V-shaped recovery.
Decelerating. At the midpoint ($135M), this is down ~19% YoY vs 25Q1 ($166M). The continued drag from TT and APM operational constraints (outages, cost absorption) is offsetting TSS seasonality.
Accelerating. Implies growth of 8-21% vs FY25 ($742M). Management expects pricing strength in TT and continued Opteon adoption to drive the recovery, alongside cost savings.
Stable. The target is relatively modest compared to the 72% achieved in Q4, reflecting the need to rebuild working capital as volumes recover.
Key Questions
TT Margin Recovery Timeline
With TT margins at 4% in Q4 and a soft Q1 guidance, what is the specific bridge to get back to mid-teen margins? How much of the Dec 1 price increase has been accepted by the market?
APM Structural Costs
APM margins collapsed to 4% despite it being a 'growth' segment. How much of this is temporary inventory charges vs. structural deleveraging from the SPS Capstone exit and market weakness?
Leverage Comfort Levels
With leverage at 4.7x and Q1 EBITDA guided down YoY, are there covenants or credit rating risks investors should worry about before the Kuan Yin sale proceeds arrive?